Fromkin Andrew J.
SEC Form 4 history for the last 180 days across 1 company, 10 transactions and 1 filing.
Period: Last 180 days
Trade dates in this period: May 28, 2026 – May 28, 2026
Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.
Latest insider transactions
Form 4 filings from the last 180 days.| Company | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $0View disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR SellForm 4 code S. Open-market or private sale of a non-derivative or derivative security. | −$7.06MView disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR SellForm 4 code S. Open-market or private sale of a non-derivative or derivative security. | −$375kView disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $239kView disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $651kView disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $568kView disclosure → | |
IMVTImmunovant, Inc. | DirectorDIR Option exerciseForm 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3. | $158kView disclosure → |
Latest Form 4 facts
Quick context from source filings
The insider reported a sale at Immunovant, Inc. on May 28, 2026 valued at $7,063,306.08.
Review SEC filingNo open-market insider purchase is available.
Monthly open-market activity
Last 1 reported month · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| May 2026 | 0 | 2 | $0 | $7,438,111.20 | −$7,438,111.20 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Counts cover all available history, including outside the summary period
Open-market buy performance
90-day forward return on this insider's open-market purchases
A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
6 observations · May 28, 2026 – May 28, 2026. Window ends at the latest available report, not today.
View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| May 28, 2026 | 131,400 | May 29, 2026 | View transaction |
| May 28, 2026 | 202,892 | May 29, 2026 | View transaction |
| May 28, 2026 | 280,073 | May 29, 2026 | View transaction |
| May 28, 2026 | 296,333 | May 29, 2026 | View transaction |
| May 28, 2026 | 284,850 | May 29, 2026 | View transaction |
| May 28, 2026 | 74,382 | May 29, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Fromkin Andrew J. Insider Activity FAQ
SEC Form 4 context
Who is Fromkin Andrew J.?
Fromkin Andrew J. is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001341896.
Which companies has Fromkin Andrew J. reported transactions for?
Immunovant, Inc.
When was Fromkin Andrew J.'s latest insider buy?
No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.
When was Fromkin Andrew J.'s latest insider sale?
The insider reported a sale at Immunovant, Inc. on May 28, 2026 valued at $7,063,306.08.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.